Andy Karabajakian

1.1k total citations · 1 hit paper
19 papers, 684 citations indexed

About

Andy Karabajakian is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andy Karabajakian has authored 19 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Otorhinolaryngology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andy Karabajakian's work include Head and Neck Cancer Studies (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Diagnosis and Treatment (5 papers). Andy Karabajakian is often cited by papers focused on Head and Neck Cancer Studies (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Diagnosis and Treatment (5 papers). Andy Karabajakian collaborates with scholars based in France. Andy Karabajakian's co-authors include Jérôme Fayette, Christophe Le Tourneau, Vincent Servois, Virginia Palomar Coloma, Caroline Even, Xavier Paolettí, J. Guigay, Esma Saâda-Bouzid, Delphine Loirat and Frédéric Peyrade and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

Andy Karabajakian

19 papers receiving 674 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

2017 449 citations Esma Saâda-Bouzid, Andy Karabajakian et al. Annals of Oncology profile →

Peers

Andy Karabajakian

ONCOL

PRM

OTORH

IMMUN

SURGE

Amy Meister United States

Xinxin Shu United States

Virginia Palomar Coloma France

Christie J. Lau United States

Su Mei Cao China

Ruth Gabriela Herrera Gómez France

Annette M. Lim Australia

Willa Shi Canada

Chang Shu Wang Canada

Amy Meister United States

Andy Karabajakian

551 ×1.0

ONCOL

240 ×1.0

PRM

206 ×1.3

OTORH

136 ×1.0

IMMUN

104 ×0.9

SURGE

Citations per year, relative to Andy Karabajakian Andy Karabajakian (= 1×) peers Amy Meister

Countries citing papers authored by Andy Karabajakian

Since Specialization

Citations

This map shows the geographic impact of Andy Karabajakian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Karabajakian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Karabajakian more than expected).

Fields of papers citing papers by Andy Karabajakian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Karabajakian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Karabajakian. The network helps show where Andy Karabajakian may publish in the future.

Co-authorship network of co-authors of Andy Karabajakian

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Karabajakian. A scholar is included among the top collaborators of Andy Karabajakian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Karabajakian. Andy Karabajakian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Foy, Jean‐Philippe, et al.. (2024). Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes. Oral Oncology. 149. 106680–106680. 4 indexed citations

Neidhardt, Eve‐Marie, et al.. (2024). Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.. Journal of Clinical Oncology. 42(16_suppl). e18027–e18027. 1 indexed citations

Karabajakian, Andy, Catherine Genestie, Pierre Méeus, et al.. (2023). Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG. Bulletin du Cancer. 110(7-8). 836–843. 2 indexed citations

Fayette, Jérôme, Esma Saâda-Bouzid, Claire Cropet, et al.. (2023). Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.. Journal of Clinical Oncology. 41(16_suppl). 6044–6044. 2 indexed citations

Afshar, Mohammad, Valéry Attignon, Jebrane Bouaoud, et al.. (2023). Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment.. Journal of Clinical Oncology. 41(16_suppl). e14652–e14652. 2 indexed citations

Karabajakian, Andy, Isabelle Ray‐Coquard, & Jean‐Yves Blay. (2022). Molecular Mechanisms of Kaposi Sarcoma Development. Cancers. 14(8). 1869–1869. 12 indexed citations

Karabajakian, Andy, Jebrane Bouaoud, Maud Kamal, et al.. (2021). Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncology. 119. 105368–105368. 23 indexed citations

Ortiz‐Cuaran, Sandra, Jebrane Bouaoud, Andy Karabajakian, Jérôme Fayette, & Pierre Saintigny. (2021). Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Frontiers in Oncology. 11. 614332–614332. 41 indexed citations

Karabajakian, Andy, Nicolas Gadot, Jean‐Yves Blay, et al.. (2020). Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. Oncotarget. 11(18). 1618–1628. 12 indexed citations

10.

Karabajakian, Andy, et al.. (2019). Induction chemotherapy in head and neck cancers: Results and controversies. Oral Oncology. 95. 164–169. 67 indexed citations

11.

Karabajakian, Andy, et al.. (2019). HNSCC and Immunotherapy: The Beginning of a Long Story. Journal of Molecular Biomarkers & Diagnosis. 10(1). 1 indexed citations

12.

Karabajakian, Andy, et al.. (2019). Head and neck cancer and immunotherapy: current knowledge and perspective. Journal of Cancer Metastasis and Treatment. 2019. 3 indexed citations

13.

Karabajakian, Andy, et al.. (2018). Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief. Cancers. 11(1). 15–15. 19 indexed citations

14.

Dalban, Cécile, Andy Karabajakian, Eve‐Marie Neidhardt, et al.. (2018). Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget. 9(31). 22038–22046. 13 indexed citations

15.

Saâda-Bouzid, Esma, Andy Karabajakian, Virginia Palomar Coloma, et al.. (2017). Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology. 28(7). 1605–1611. 449 indexed citations breakdown →

16.

Karabajakian, Andy, et al.. (2017). Chemotherapy for recurrent/metastatic head and neck cancers. Anti-Cancer Drugs. 28(4). 357–361. 17 indexed citations

17.

Karabajakian, Andy, et al.. (2017). Chemotherapy for localized head and neck squamous cell cancers. Anti-Cancer Drugs. 28(4). 362–368. 5 indexed citations

18.

Karabajakian, Andy, et al.. (2017). Nivolumab in Recurrent/Metastatic Head and Neck Cancers. Future Oncology. 14(7). 603–609. 4 indexed citations

19.

Saâda-Bouzid, Esma, Andy Karabajakian, Virginia Palomar Coloma, et al.. (2016). Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors.. Journal of Clinical Oncology. 34(15_suppl). 6072–6072. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact